160
Participants
Start Date
July 21, 2023
Primary Completion Date
June 17, 2025
Study Completion Date
May 28, 2026
Tislelizumab
Administered intravenously
BGB-A425
Administered intravenously
LBL-007
Administered intravenously
National Cheng Kung University Hospital, Tainan City
North Shore Private Hospital, St Leonards
Nepean Hospital, Kingswood
Northeast Health Wangaratta, Wangaratta
Greenslopes Private Hospital, Greenslopes
Gold Coast Private Hospital, Gold Coast
Cancer Research South Australia, Adelaide
St John of God, Murdoch, Murdoch
Ramathibodi Hospital Mahidol University, Bangkok
National Cancer Center, Goyang-si
Siriraj Hospital, Bangkok
Taipei Veterans General Hospital, Taipei
Seoul National University Bundang Hospital, Seongnam-si
Istituto Clinico Humanitas, Rozzano
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan
Istituto Europeo Di Oncologia, Milan
Tr Trakya University Health Research and Application Center (Hospital), Edirne
Oncology and Hematology Associates of Southwest Virginia, Inc (Us Oncology Research), Blacksburg
Scientific Institute of Pavia Maugeri, Pavia
Hospital Clinico San Carlos, Madrid
Florida Cancer Specialist Research Institute Panhandle, Tallahassee
Florida Cancer Specialist Research Institute Lake Nona, Orlando
Medical Park Izmir Hospital, Izmir
Srinagarind Hospital (Khon Kaen University), Muang
China Medical University Hospital, Taichung
University of Kentucky Markey Cancer Center, Lexington
Hospital Universitario Virgen Del Rocio, Seville
Keimyung University Dongsan Hospital, Dalseogu
Ico Site Rene Gauducheau, SaintHerblain
Changhua Christian Hospital, Changhua
Hospital Universitario Miguel Servet, Zaragoza
Institut Curie Paris, Paris
Rocky Mountain Cancer Centers, Llp(Us Oncology Research), Lone Tree
Valkyrie Clinical Trials, Los Angeles
Songklanagarind Hospital (Prince of Songkhla University), Hat Yai
Stanford Medicine, Stanford
Institut Gustave Roussy, Villejuif
Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver
Cancer Care Northwest, Spokane Valley
Beijing Tongren Hospital, Cmu, Beijing
Beijing Cancer Hospital, Beijing
The First Hospital of Jilin University, Changchun
National Cancer Centre Singapore, Singapore
Shanghai East Hospital, Shanghai
The First Affiliated Hospital of Soochow University, Suzhou
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei
Shandong Cancer Hospital, Jinan
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Xiangya Hospital of Central South University, Changsha
The Second Xiangya Hospital of Central South University, Changsha
Hunan Cancer Hospital, Changsha
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
Sun Yat Sen University Cancer Center, Guangzhou
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Sichuan Cancer Hospital and Institute, Chengdu
West China Hospital, Sichuan University, Chengdu
The First Affiliated Hospital of Chongqing Medical University, Chongqing
British Columbia Cancer Agency the Vancouver Centre, Vancouver
The Ottawa Hospital Cancer Centre, Ottawa
Centre Antoine Lacassagne, Nice
Arensia Exploratory Medicine Llc, Tbilisi
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Ico Lhospitalet Hospital Duran I Reynals, Barcelona
Royal Marsden Hospital, London
Royal Marsden Hospital Sutton, Sutton
Lead Sponsor
BeiGene
INDUSTRY